Evidence map›Paper›PMID 42068502›Full record

ReviewInfectious diseases and therapy2026

Infections Caused by Fusobacterium Species: Microbiology, Clinical Syndromes and Management: A Narrative Review.

Michal Paret, Guy Katzenellenbogen, Tal Zilberman, Michal Stein, Ili Margalit, Dafna Yahav

Abstract readReview
In one paragraph

Review in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. FulminantInfectious disease reports · 2026
    Article
  2. Prognostic value of the identified genus of anaerobic bacteria in bloodstream infection beyond host-related risk factors: a five-year retrospective cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michal ParetPediatric Infectious Diseases Unit, Sheba Medical Center, 2 Sheba Road, 52621, Ramat Gan, Israel.
Guy KatzenellenbogenPediatric Infectious Diseases Unit, Sheba Medical Center, 2 Sheba Road, 52621, Ramat Gan, Israel.
Tal ZilbermanFaculty of Medical & Health Sciences, Tel Aviv, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.
Michal SteinPediatric Infectious Diseases Unit, Sheba Medical Center, 2 Sheba Road, 52621, Ramat Gan, Israel.
Ili MargalitFaculty of Medical & Health Sciences, Tel Aviv, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel.
Dafna YahavFaculty of Medical & Health Sciences, Tel Aviv, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel. dafna.yahav@gmail.com.ORCID http://orcid.org/0000-0003-3181-9791

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fusobacterium spp. are Gram-negative, obligate anaerobic bacteria associated with a broad clinical spectrum, including head and neck infections; soft tissue infections; gastrointestinal and genitourinary infections; and bacteremia without an identified source. Clinical manifestations vary by species and site of colonization. F. necrophorum is linked to head and neck infections that may culminate in Lemierre syndrome, a life-threatening septic thrombophlebitis of the internal jugular vein. Although Fusobacterium bacteremia is uncommon, it is associated with substantial mortality. F. necrophorum bacteremia may occur as a complication of head and neck infection in younger, healthy individuals, whereas F. nucleatum bacteremia is reported predominantly in older patients with malignancy, secondary to an abdominal source or without an identified origin. Fusobacterium isolates are usually susceptible to penicillins, cephalosporins, aminopenicillins with β-lactamase inhibitors, carbapenems, and metronidazole, while resistance to clindamycin and moxifloxacin has been increasingly reported. Because susceptibility testing is not routinely performed and susceptibility data remain limited, severe infections are commonly treated with a β-lactam/β-lactamase inhibitor, a carbapenem, or a β-lactam in combination with metronidazole. This review provides an overview of the microbiology, clinical spectrum, and treatment of Fusobacterium spp.

Indexed as

AnaerobesFusobacteriumLemierre syndromeSeptic thrombophlebitisSusceptibilityTreatment

Identifiers

PMID42068502
PMCPMC13219549

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.